Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
57.86
+0.98 (1.72%)
At close: Feb 6, 2026, 4:00 PM EST
56.00
-1.86 (-3.21%)
After-hours: Feb 6, 2026, 6:26 PM EST

Monopar Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
5.743.163.232.952.632.44
Research & Development
15.8913.015.67.596.494.07
Operating Expenses
21.6216.168.8310.549.136.51
Operating Income
-21.62-16.16-8.83-10.54-9.13-6.51
Interest & Investment Income
2.180.40.430.020.020.08
Other Non Operating Income (Expenses)
00.17----
EBT Excluding Unusual Items
-19.44-15.59-8.4-10.52-9.1-6.43
Other Unusual Items
-----0.12
Pretax Income
-19.44-15.59-8.4-10.52-9.1-6.3
Net Income
-19.44-15.59-8.4-10.52-9.1-6.3
Net Income to Common
-19.44-15.59-8.4-10.52-9.1-6.3
Shares Outstanding (Basic)
743322
Shares Outstanding (Diluted)
743322
Shares Change (YoY)
97.28%37.09%8.70%1.97%13.82%17.56%
EPS (Basic)
-2.99-4.11-3.04-4.13-3.65-2.88
EPS (Diluted)
-2.99-4.11-3.04-4.13-3.65-2.88
EBIT
-21.62-16.16-8.83-10.54-9.13-6.51
Updated Nov 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q